With great expectations we read the report by Kimura et al. (1) in which the authors describe polyclonal antibody NH27, applicable on human tissues fixed with 4% paraformaldehyde and embedded in paraffin. The reported immunostaining patterns with this rabbit antibody raised against a 5 5 KD fusion protein containing a part of the human androgen receptor (hAR) molecule triggered our concern with regard to its specificity.
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In our experience, monoclonal and polydonal anti-hAR antibodies generated by the synthetic peptide strategy (2,3) were often suitable for immunocytochemical detection of the hAR in cells transfected with AR coding DNA. However, depending on the synthetic peptide used for immunization, several anti-hAR antibodies displayed crossreactivity with other steroid receptors and/or with smooth muscle of gastrointestinal, respiratory, and urinary tract.
Unfortunately contains detailed information on the specificity of polyclonal NH27, apart from its reactivity with a 110 KD protein. Therefore, no data were provided regarding the reactivity of NH27 with other steroid receptors. Moreover, no well-established negative controls for hAR, i.e., lymphoid tissues, were included in the immunohistochemical study by Kimura et al. (1) . The observation of an increased nuclear immunoreactivity in immune sera as compared to a preimmune serum only proves a successful immunization procedure. The claimed similarity in immunostaining patterns of NH27 and the well-characterized anti-hAR antibody AN 1-15 ( 5 ) on human prostate tissues (6) is also no guarantee of NH27 specificity. In fact, the tissue distribution of AR is not yet fully established by independent methods and criteria for the specificity of an antibody raised against AR are not yet set.
Furthermore, a very unfortunate "slip of the pen" in the paper by Kimura et al. (1) was their way of citing the results of our group. The correct data provided by our study (7) are given in Table 1 . It is clear from these data that we do not agree with the implication by Kimura et al. that their immunohistochemical observations on AR expression in paraffin-embedded tissue are in line with those of lskada et al. (8) and our group (7) . We also would like to add that the data of Takada et al. (8) were mainly based on the study of rat and mouse tissues, and the occurrence of species differences in AR expression can certainly not be excluded. While we await further data on biochemical and immunohistochemical specificity of polyclonal anti-hAR antibody NH27 to assess the reliability of the results presented, the reader must be referred to Ruizeveld de Winter et al. (7) and Ekeda et al. (8) for a detailed description of AR expression in human and rat tissues, respectively.
